[go: up one dir, main page]

SG11202103666PA - Methods and Compositions for Editing RNAs - Google Patents

Methods and Compositions for Editing RNAs

Info

Publication number
SG11202103666PA
SG11202103666PA SG11202103666PA SG11202103666PA SG11202103666PA SG 11202103666P A SG11202103666P A SG 11202103666PA SG 11202103666P A SG11202103666P A SG 11202103666PA SG 11202103666P A SG11202103666P A SG 11202103666PA SG 11202103666P A SG11202103666P A SG 11202103666PA
Authority
SG
Singapore
Prior art keywords
compositions
methods
rnas
editing
editing rnas
Prior art date
Application number
SG11202103666PA
Inventor
Wensheng Wei
Liang Qu
Zongyi Yi
Shiyou Zhu
Chunhui Wang
Zhongzheng Cao
Zhuo Zhou
Pengfei Yuan
Original Assignee
Univ Beijing
Edigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70163607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202103666P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Beijing, Edigene Inc filed Critical Univ Beijing
Publication of SG11202103666PA publication Critical patent/SG11202103666PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/34Allele or polymorphism specific uses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
SG11202103666PA 2018-10-12 2019-10-12 Methods and Compositions for Editing RNAs SG11202103666PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018110105 2018-10-12
CN2019082713 2019-04-15
PCT/CN2019/110782 WO2020074001A1 (en) 2018-10-12 2019-10-12 Methods and Compositions for Editing RNAs

Publications (1)

Publication Number Publication Date
SG11202103666PA true SG11202103666PA (en) 2021-05-28

Family

ID=70163607

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103666PA SG11202103666PA (en) 2018-10-12 2019-10-12 Methods and Compositions for Editing RNAs

Country Status (21)

Country Link
US (2) US20210355494A1 (en)
EP (3) EP4527931A1 (en)
JP (2) JP7252328B2 (en)
KR (1) KR102666695B1 (en)
CN (4) CN116218836A (en)
AU (2) AU2019357450B2 (en)
BR (1) BR112021006844A8 (en)
CA (1) CA3115864A1 (en)
CL (1) CL2021000880A1 (en)
CO (1) CO2021005956A2 (en)
CR (1) CR20210243A (en)
DK (1) DK3864152T5 (en)
EC (1) ECSP21033637A (en)
ES (1) ES2962434T3 (en)
IL (1) IL282191A (en)
MX (1) MX2021004187A (en)
PE (1) PE20211402A1 (en)
PH (1) PH12021550805A1 (en)
SG (1) SG11202103666PA (en)
TW (1) TW202028466A (en)
WO (1) WO2020074001A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2574769A (en) 2017-03-03 2019-12-18 Univ California RNA Targeting of mutations via suppressor tRNAs and deaminases
CA3115864A1 (en) * 2018-10-12 2020-04-16 Peking University Methods and compositions for editing rnas
CA3126947A1 (en) 2019-01-22 2020-07-30 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
JP2022519184A (en) 2019-01-22 2022-03-22 コロ バイオ, インコーポレイテッド RNA editing oligonucleotides and their use
CN113573717A (en) 2019-01-22 2021-10-29 科罗生物公司 Oligonucleotides for RNA editing and their uses
WO2020211780A1 (en) 2019-04-15 2020-10-22 Edigene Inc. Methods and compositions for editing rnas
WO2021008447A1 (en) 2019-07-12 2021-01-21 Peking University Targeted rna editing by leveraging endogenous adar using engineered rnas
AU2020395113A1 (en) 2019-12-02 2022-06-09 Shape Therapeutics Inc. Therapeutic editing
US20230067480A1 (en) 2019-12-30 2023-03-02 Edigene Therapeutics (Beijing) Inc. Method for treating usher syndrome and composition thereof
PH12022551595A1 (en) 2019-12-30 2023-11-29 Edigene Therapeutics Beijing Inc Leaper technology based method for treating mps ih and composition
KR20220162168A (en) * 2020-04-15 2022-12-07 에디진 테라퓨틱스 (베이징) 인크. Treatment methods and drugs for Hurler syndrome
US20240011028A9 (en) * 2020-04-22 2024-01-11 Shape Therapeutics Inc. Compositions and Methods Using SNRNA Components
AU2021279027A1 (en) * 2020-05-28 2022-12-08 Korro Bio, Inc. Methods and compositions for the ADAR-mediated editing of SERPINA1
CN113897359A (en) * 2020-07-06 2022-01-07 博雅辑因(北京)生物科技有限公司 Improved RNA editing method
CA3185231A1 (en) 2020-07-06 2022-01-13 Pengfei YUAN Improved rna editing method
IL278401A (en) 2020-10-29 2022-05-01 Yeda Res & Dev Polynucleotides for rna editing and methods of using same
US20250270543A1 (en) * 2021-01-04 2025-08-28 The Regents Of The University Of California Programmable rna editing in vivo via recruitment of endogenous adars
EP4277990A4 (en) * 2021-01-12 2025-02-12 Peking University Targeted rna editing by leveraging endogenous adar using engineered rnas
IL309025A (en) * 2021-06-15 2024-02-01 Massachusetts Inst Technology Deaminase-based rna sensors
US20240279656A1 (en) * 2021-06-29 2024-08-22 Shape Therapeutics Inc. Engineered Guide RNAs and Polynucleotides
TW202321451A (en) * 2021-08-18 2023-06-01 北京大學 Engineered adar-recruiting rnas and methods of use thereof
WO2023060186A1 (en) 2021-10-07 2023-04-13 Hepatx Corporation Methods of tracking donor cells in a recipient
KR20240135602A (en) * 2021-10-29 2024-09-11 듀크 유니버시티 Compositions and systems for RNA-programmable cell editing and methods for making and using the same
WO2023143539A1 (en) * 2022-01-28 2023-08-03 Edigene Therapeutics (Beijing) Inc. Engineered adar-recruiting rnas and methods of use thereof
WO2023185231A1 (en) * 2022-04-02 2023-10-05 Edigene Therapeutics (Beijing) Inc. Engineered adar-recruiting rnas and methods of use for usher syndrome
WO2024228735A2 (en) * 2022-07-15 2024-11-07 Georgia Tech Research Corporation Anti-sars-cov-1 and anti-sars-cov-2 activatable rnase guide sequences
AU2023364059A1 (en) * 2022-10-18 2025-05-08 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising programmable snrnas for rna editing
CN118620958A (en) * 2023-03-08 2024-09-10 广州医科大学 A method for preparing antigen epitope
WO2024197951A1 (en) * 2023-03-31 2024-10-03 时夕(广州)生物科技有限公司 Sequence for forming editing substrate together with rna editing target site
CN118853661A (en) * 2023-04-28 2024-10-29 时夕(广州)生物科技有限公司 Methods, compositions and uses of editing RNA
WO2024235283A1 (en) * 2023-05-16 2024-11-21 Peking University Method of modulating rna splicing
CN119505015B (en) * 2024-11-15 2025-10-17 北京大学 Fusion protein and application method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101297830B1 (en) * 2010-09-10 2013-08-19 한국생명공학연구원 Novel structure-specific RNA binding protein and method for array detection of label-free microRNA using the same
EP3230445B1 (en) 2014-12-12 2024-01-24 Tod M. Woolf Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
EP3712269A1 (en) * 2014-12-17 2020-09-23 ProQR Therapeutics II B.V. Targeted rna editing
US11390865B2 (en) * 2015-07-14 2022-07-19 Fukuoka University Method for introducing site-directed RNA mutation, target editing guide RNA used in the method and target RNA-target editing guide RNA complex
US11396672B2 (en) * 2015-08-31 2022-07-26 The University Of Chicago Composition and methods for detecting adenosine modifications
DE102015012522B3 (en) * 2015-09-26 2016-06-02 Eberhard Karls Universität Tübingen Methods and substances for directed RNA editing
WO2017220751A1 (en) * 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
US10941402B2 (en) * 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
GB2574769A (en) * 2017-03-03 2019-12-18 Univ California RNA Targeting of mutations via suppressor tRNAs and deaminases
AU2018234825B2 (en) * 2017-03-15 2020-12-17 Massachusetts Institute Of Technology Novel CAS13B orthologues CRISPR enzymes and systems
EP3684397A4 (en) * 2017-09-21 2021-08-18 The Broad Institute, Inc. SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
CA3115864A1 (en) * 2018-10-12 2020-04-16 Peking University Methods and compositions for editing rnas

Also Published As

Publication number Publication date
AU2019357450B2 (en) 2023-01-12
DK3864152T3 (en) 2023-10-09
JP2021534810A (en) 2021-12-16
WO2020074001A1 (en) 2020-04-16
CN113631708A (en) 2021-11-09
US20210355494A1 (en) 2021-11-18
IL282191A (en) 2021-05-31
MX2021004187A (en) 2021-09-08
EP3864152B1 (en) 2023-08-16
EP3864152A4 (en) 2021-10-13
AU2023202184A1 (en) 2023-05-04
PE20211402A1 (en) 2021-08-02
CN115651927B (en) 2023-06-16
CO2021005956A2 (en) 2021-07-30
CL2021000880A1 (en) 2021-12-10
KR20210076082A (en) 2021-06-23
EP4306116A3 (en) 2024-04-17
BR112021006844A8 (en) 2023-03-21
ES2962434T3 (en) 2024-03-19
CN116218836A (en) 2023-06-06
EP3864152A1 (en) 2021-08-18
JP7252328B2 (en) 2023-04-04
TW202028466A (en) 2020-08-01
KR102666695B1 (en) 2024-05-23
EP4527931A1 (en) 2025-03-26
AU2019357450A1 (en) 2021-06-03
CN115651927A (en) 2023-01-31
US20210310026A1 (en) 2021-10-07
DK3864152T5 (en) 2024-08-12
CR20210243A (en) 2021-10-07
AU2023202184B2 (en) 2025-06-12
CN116042611A (en) 2023-05-02
CN113631708B (en) 2022-05-24
BR112021006844A2 (en) 2021-07-20
EP4306116A2 (en) 2024-01-17
CA3115864A1 (en) 2020-04-16
JP2023078373A (en) 2023-06-06
ECSP21033637A (en) 2021-08-31
PH12021550805A1 (en) 2021-10-04

Similar Documents

Publication Publication Date Title
IL282191A (en) Methods and compositions for editing rnas
IL287248A (en) Methods and compositions for editing rnas
IL273817A (en) Compositions and methods for editing rna
IL277837A (en) Compositions and methods for gene editing
IL277079A (en) Cartyrin compositions and methods for use
IL280134A (en) Anti-cd112r compositions and methods
SG11202103571XA (en) Compositions and methods for immunotherapy
IL271232A (en) Compositions and methods for genome editing
GB201905559D0 (en) Composition and method
EP3256487A4 (en) Compositions and methods for epigenome editing
SG11202003790PA (en) Composition and method
IL290840A (en) Compositions and methods for cd123 modification
IL275539A (en) Compositions and methods for inhibiting aldh2 expression
SG11202104448WA (en) Compositions and methods
IL274524A (en) Compositions and methods for aquaculturing
GB201817444D0 (en) Methods and compositions
GB201909542D0 (en) Composition and method
IL290325A (en) Biopharmacuetical compositions and related methods
IL286587A (en) D-metyrosine compositions and methods for preparing same
GB201819987D0 (en) Methods and compositions
SG11202104346YA (en) Compositions and methods for nhej-mediated genome editing
GB2579687B (en) Composition and method
GB201804092D0 (en) Methods and compositions
GB201914777D0 (en) Composition and method
SG11202108262VA (en) Bacterialcidal methods and compositions